The incidence of BRAF mutations ranges from 1 to 5% in non-small-cell lung cancer (NSCLC), and is most common in lung adenocarcinomas, where BRAF V600E mutations account for more than 50% of all the BRAF mutation cases (O'Leary et al. 2019). This evidence concerns the gene BRAF and lung adenocarcinoma.